
|Articles|January 8, 2008
NiCox and Pfizer launch glaucoma trial
NicOx and Pfizer have initiated a dose-ranging Phase II clinical study of PF-03187207, a treatment for glaucoma, in Japan.
Advertisement
NicOx and Pfizer have initiated a dose-ranging Phase II clinical study of PF-03187207, a treatment for glaucoma, in Japan.
PF-03187207 is the lead development compound generated under the collaboration between Pfizer and NicOx, which is concentrating on the research and development of nitric oxide-donating prostaglandin F2-alpha analogues for the treatment of glaucoma.
The Japanese study will compare the safety and efficacy of the PF-03187207 with latanoprost (Xalatan; Pfizer). The compound is already being examined in a Phase II proof-of-concept study in the US.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD
3
Think outside the cone: Applying the Gulani Keratoconus Classification
4
Johnson & Johnson spotlights contrast data, 1 million TECNIS implants, and SmartLOAD delivery
5


















